Tavotek Bio Raises $20 Million-plus for Novel US-China Antibodies

Tavotek Biotherapeutics, a Philadelphia-Suzhou biotech, raised more than $20 million in Round A1 and Round A2 financings over the last two months. Tavotek said it would use the capital for CMC production and IND filings of its three lead antibody drugs. It will also expand its bispecific/multispecific antibody pipelines and intracellular peptide (MIP) programs for autoimmune and oncology indications. In 2019, Tavotek was founded with an initial round from Apricot Capital. Tavotek has R&D operations in the Philadelphia area and Suzhou . More details.... Share this with colleagues: // //